Acute pancreatitis due to different semaglutide regimens: An updated meta-analysis

Simple item page
dc.contributor.authorWalter Masson
dc.contributor.authorMartín Lobo
dc.contributor.authorLeandro Barbagelata
dc.contributor.authorAugusto Lavalle-Cobo
dc.contributor.authorJuan P. Nogueira
dc.date.accessioned2026-08-25T23:34:48Z
dc.date.available2026-08-25T23:34:48Z
dc.date.issued2024-01-07
dc.description.abstractSemaglutide is widely used for type 2 diabetes and weight management, although concerns remain regarding its pancreatic safety. This updated meta-analysis evaluated the risk of acute pancreatitis associated with different semaglutide regimens. Randomized placebo-controlled trials were systematically reviewed following PRISMA guidelines, and global and stratified analyses were performed. Twenty-one trials involving 34,721 patients were included. Semaglutide was not associated with an increased risk of acute pancreatitis compared with placebo. Similar findings were observed for oral, low-dose subcutaneous, and high-dose subcutaneous regimens. These results support the pancreatic safety of semaglutide across different therapeutic regimens, although further real-world evidence remains warranted.
dc.description.sponsorshipSemaglutide; Acute pancreatitis; GLP-1 receptor agonists; Drug safety; Meta-analysis.
dc.identifier.urihttp://repositorio.uia.ac.cr/handle/123456789/5137
dc.language.isoen
dc.titleAcute pancreatitis due to different semaglutide regimens: An updated meta-analysis
dc.typeArticle
Files
Original bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
1-s2.0-S2530018024000295.pdf
Size:
1.24 MB
Format:
Adobe Portable Document Format
Download
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed to upon submission
Description:
Download
Collections
Medicina